

CURRICULUM VITAE

Name: Louis Michael Staudt

Education: M.D. University of Pennsylvania School of Medicine, 1982
Ph.D., Immunology, University of Pennsylvania School of Medicine, 1982
B.A., Harvard College, Biochemistry, Cum Laude, 1976

Work Experience

1982 – 1983 Postdoctoral Fellow, Wistar Institute, Philadelphia, PA (Laboratory of Walter Gerhard)
1983 – 1984 Intern, Internal Medicine, Presbyterian - Univ. of Penn. Medical Center, Philadelphia, Pennsylvania
1984 – 1988 Postdoctoral Fellow, Whitehead Institute for Biomedical Research, Cambridge, MA
(Laboratory of David Baltimore)
1988 – 1995 Senior Staff Fellow, Metabolism Branch, National Cancer Institute, NIH
1995 – 2001 Senior Investigator, Metabolism Branch, National Cancer Institute, NIH
2001 – present Chief, Lymphoid Malignancies Section, Metabolism Branch, CCR, National Cancer Institute, NIH
2003 – present Adjunct Professor, University of Pennsylvania School of Medicine, Philadelphia, PA
2003 – 2008 Senior Biomedical Research Service, NIH
2004 – 2013 Deputy Chief, Metabolism Branch, CCR, National Cancer Institute, NIH
2013 – present Co-Chief, Lymphoid Malignancies Branch, CCR, National Cancer Institute, NIH
2013 – present Director, Center for Cancer Genomics, National Cancer Institute, NIH

Awards and Honors

1982 Stuart Mudd Award in Microbiology, Univ. of Pennsylvania
1982 Baldwin Lucke Memorial Prize in Experimental Medicine and Biology, Univ. of Pennsylvania
1976-1982 Medical Scientist Training Program Award, Univ. of Pennsylvania
1984-1987 Fellowship, Jane Coffin Child Memorial Foundation for Cancer Research
1988-1992 Investigator Award, Cancer Research Institute
1989 Trainee Award, American Federation for Clinical Research
1992 Arthur S. Flemming Award for outstanding Federal employees
1998 NIH Director's Award – Cancer Genome Anatomy Project
2000 NIH Director's Award – Microarray Tech Group
2000 Robert Sternlicht Lecture, Case Western Reserve University School of Medicine
2001 Blass Lecture in Genetics, University of Arkansas Medical School
2001 Mary Chupp Lecturer in Hematology/Oncology, New England Medical Center
2002 Kenneth B. McCredie Memorial Lecture, Leukemia and Lymphoma Society
2002 NIH Merit Award
2003 Julia Hudson Freund Memorial Lecture, Washington University School of Medicine
2003 Peacock Memorial Lecturer in Pathology, U. of Texas Southwestern Medical Center
2003 2003 Guest Lecturer, Leukemia Research Fund, UK
2004 Elected to the Association of American Physicians
2006 NIH Director's Award
2009 William Dameshek Prize for outstanding contribution in hematology, American Society of Hematology
2010 NIH Director's Award – Lymphoma Leukemia Molecular Profiling Project
2010 NIH Merit Award – Lymphoma Leukemia Molecular Profiling Project
2011 NIH Distinguished Investigator
2013 NIH Director's Award – Matrix Screening Group
2013 Elected to the National Academy of Sciences
2014 NIH Director's Award – TCGA Team
2014 NIH Merit Award – NCI Exceptional Responders Initiative Development Team
2014 San Salvatore Prize for positive results in research in the treatment of malignant tumors

Medical License Maryland

Committees

1997-1999 Cancer Genome Anatomy Project Steering Committee, NCI
1997-2002 Microarray Steering committee, NCI
1997-1999 Co-chair, 1999 FASEB Summer Research Conference on Hematological Malignancies
1999-present Co-chair, Lymphoma/Leukemia Molecular Profiling Project, NCI
1999-2002 Steering Committee, HHMI/NIH Research Scholars Program
2000-2001 Scientific Advisory Board, Biomedical Genomics Center, Univ. of Minnesota
2000-2001 Steering Committee, NCI, Program Review Group, Lymphoma, Leukemia, Myeloma
2000-2011 Editorial Board, Genome Biology
2001-present Editorial Board, Cancer Cell
2001-2003 Co-organizer, 2003 Keystone Symposium on B Cells & Antibodies: Laboratory to Clinic
2001-2005 Steering Committee, Faculty of Genetics, Genomics and Proteomics, NCI
2002-2005 Consulting Editor, Journal of Clinical Investigation
2002-2007 Editorial Board, Immunological Reviews
2002-2003 Reviewer, Specialized Center of Research Program, Leukemia and Lymphoma Society
2002-present Scientific Advisory Board, International Conference on Malignant Lymphoma, Lugano, Switzerland
2002-2007 External Advisory Board, Dana Farber/Harvard Cancer Center
2004-present Association of American Physicians
2004-2013 Scientific Advisor, Multiple Myeloma Research Foundation
2005-2006 Education Committee for the 97th American Association for Cancer Research Annual Meeting
2006-present Scientific Advisory Board, Lymphoma Research Foundation
2007-2014 Scientific Advisory Board, Research Center for Molecular Medicine, Vienna, Austria
2008-present Tenure and Promotion Committee, Center for Cancer Research, NCI
2008-present Lymphoma Research Foundation Follicular Lymphoma Consortium Executive Committee
2008-2009 Co-Chairman, Program Committee, 2009 AACR Annual Meeting
2009 Scientific Advisory Board, Cancer Genome Project, Wellcome Trust Institute, Cambridge, UK
2009-present Scientific Advisory Board, Burkitt's Lymphoma Foundation
2009-present Scientific Advisory Board, HIV+ DLBCL Project
2010-present Associate Editor, Journal of Experimental Medicine
2010-present National Cancer Institute DLBCL Working Group
2010-present Chair, The Cancer Genome Atlas (TCGA) Disease Working Group on Non-Hodgkin's Lymphoma
2011-2013 External advisory committee, Centre Immunologie Marseilles-Luminy, Marseilles, France
2011-present CLL Genome Project Advisory Board, Barcelona, Spain
2011-2012 Scientific Review Committee Landon Foundation-AACR INNOVATOR Award
2011-2013 External Scientific Committee, The Cancer Genome Atlas (TCGA)
2012-present Board of Reviewing Editors, eLife
2013-2014 Co-Chairman, Program Committee, 2014 AACR Annual Meeting
2012-present Co-organizer of the AACR meeting on Synthetic Lethality in Cancer, 2013
2013-present Co-organizer of the 2014 Keystone symposium on NF- κ B
2013-present Co-organizer of the 2014 ASH meeting on lymphoma biology
2014-present Co-organizer of the 2014 ESH International Conference on New Concepts in B Cell Malignancies
2014-present Editorial Board, Cold Spring Harbor Molecular Case Studies

Patents

USPN 7,329,502 ZAP-70 protein expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma
USPN 7,711,492 Methods for diagnosing lymphoma types
USPN 8,131,457 Methods for identifying, diagnosing, and predicting survival of lymphomas
Patent application Survival predictor for diffuse large B cell lymphoma
PCT/US2009/046421 (US Patent App. Pub. No. US-2011-0195064-A1)
Patent application Methods of treating ABC DLBCL using inhibitors of Bruton's tyrosine kinase
(U.S. Provisional Patent Application No. 20120071497)
Patent application Inhibitors of the linear ubiquitin chain assembly complex (LUBAC) and related methods
(U.S. Provisional Patent Application No. 61/789,064)

Recent Invited Lectures

Dec 2009 Presidential Symposium, American Society of Hematology Annual Meeting, New Orleans, LA
Jan 2010 Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Jan 2010 Keynote address, Western Medical Student Forum, Monterey, CA
Mar 2010 Translational Genomics, Bethesda, MD
Mar 2010 Mayo Clinic, Rochester, MN
Apr 2010 Keynote Speaker, 2010 Geoffrey Beene Cancer Research Retreat, Memorial Sloan-Kettering Cancer Center. Skytop, PA

Apr 2010 The Feinstein Institute for Medical Research, North Shore - LIJ Health System, Manhasset, NY
Apr 2010 Henry Kunkel Society Annual Conference 2010, New York, NY
May 2010 Deutsche Forschungsgemeinschaft "Hinterzarter Kreis" for Cancer Research, Lake Como, Italy
May 2010 4th International Conference on Innovative Therapies for Lymphoid Malignancies, Palermo, Sicily
July 2010 Aspen Cancer Conference, Aspen, CO
Sept 2010 Etiology of Chromosomal Translocations, NIH, Bethesda, MD
Sept 2010 72nd Annual Meeting of the Japanese Society of Hematology, Yokohama, Japan
Oct 2010 5th International Conference on Gene Regulation in Lymphocyte Development, Crete, Greece
Oct 2010 3rd International Symposium on Regulators of Adaptive Immunity, Erlangen, Germany
Oct 2010 24th Annual CABM Symposium, "Cancer: Progress and Prospects", Newark, NJ
Nov 2010 Aggressive Lymphomas, Bologna, Italy
Nov 2010 French Society for Immunology Annual Meeting, Marseilles, France
Dec 2010 American Society of Hematology Annual Meeting, Orlando, FL
Jan 2011 Cambridge University, Cambridge, UK
Feb 2011 AACR Systems Biology meeting, La Jolla, CA
Apr 2011 Keystone Symposium on B cells. Whistler, Canada
May 2011 NF- κ B, Univ. of Cincinnati Cancer Center Symposium. Cincinnati, OH
May 2011 New York Univ. School of Medicine, Immunology Graduate Group, New York, NY
May 2011 Joy Faith Knapp Memorial Lecture, Univ. of Chicago, Chicago, IL
May 2011 California Institute of Technology, Dept. of Biology, Pasadena, CA
June 2011 EMBO Synthetic Lethality Workshop, Vienna, Austria
June 2011 Forum on Immunology and Immunotherapy of Cancer, Japanese Society for the Promotion of Science (JSPS), Washington, DC

June 2011 Burkitt's lymphoma symposium, Trinity College, Dublin, Ireland
July 2011 Sanford-Burnham Institute, La Jolla, CA
July 2011 NCI Translational Science meeting, Washington, DC
Aug 2011 FASEB conference on Hematological Malignancies, Saxton's River, VT
Sept 2011 The JAK-STAT Pathway: 20 Years From Discovery to Drugs
Sept 2011 Univ. of California, Berkeley, Dept. of Molecular and Cell Biology, Berkeley, CA
Oct 2011 Duke Univ. School of Medicine, Dept. of Immunology, Durham, NC
Oct 2011 Massachusetts General Hospital, Boston, MA
Nov 2011 Frontiers in Cancer Science, Singapore
Nov 2011 Banbury Conference: MYC and the Pathway to Cancer, Cold Spring Harbor, NY
Dec 2011 Grand Rounds, UMass Medical School, Dept. of Medicine
Jan 2012 AACR Non-coding RNA meeting, Miami, FL
Jan 2012 Epigenetic Regulation in Disease, Vienna, Austria
Jan 2012 Midwinter Conference of Immunologists, Asilomar, CA
Feb 2012 Translational Research Conference, Johns Hopkins School of Medicine, Baltimore, MD
Feb 2012 Helen Diller Cancer Center, Univ. of California, San Francisco, San Francisco, CA
Feb 2012 Children's Hospital of Philadelphia Research Institute, Philadelphia, PA
Mar 2012 Keystone Symposium, Regulation of Lymphocyte Signaling, Keystone, CO
Mar 2012 Opening Plenary Session, AACR Annual Meeting, Chicago, IL
Apr 2012 NCI Workshop on Precision Medicine, Bethesda MD
May 2012 Grand Rounds, Univ. of Nebraska School of Medicine, Omaha NE
May 2012 NF- κ B meeting, Univ. of North Carolina School of Medicine, Chapel Hill, NC
May 2012 Stanley Korsmeyer Keynote Speaker, 5th International Palermo Conference on Innovative Therapies for Lymphoid Malignancies, Palermo, Italy
June 2012 Keynote Speaker, Henry Kunkel Society Annual Meeting, Berlin, Germany

June 2012 Max Delbruck Center for Molecular Medicine, Berlin Germany
 June 2012 Charité – Medical University of Berlin, Berlin, Germany
 July 2012 NCI conference on Burkitt lymphoma, Philadelphia, PA
 Oct 2012 6th International Workshop on Myeloma Pharmacogenomics on Novel Therapeutics, Scottsdale, AZ
 Oct 2012 Wistar Institute Distinguished Alumni Lecture, Philadelphia, PA
 Oct 2012 Annual meeting, German,Austrian,Swiss Societies of Hematology and Oncology, Stuttgart, Germany
 Oct 2012 Oncology at the Limits, London, UK
 Nov 2012 Annual meeting of The Cancer Genome Atlas (TCGA), Crystal City, VA
 Dec 2012 American Society of Hematology Annual Meeting, Atlanta, GA
 Feb 2013 Keystone Symposium: B cell development and function, Keystone, CO
 Feb 2013 1st Annual Expert Forum on B-cell Receptor Signaling, Santa Monica, CA
 Mar 2013 Memorial Sloan Kettering Cancer Center, Dept. of Pediatrics, New York, NY
 Apr 2013 AACR Annual Meeting, Washington, DC
 May 2013 American Association of Immunologists Annual Meeting, Honolulu, HI
 May 2013 AACR meeting on Synthetic Lethal Approaches to Cancer Vulnerabilities, Bellevue, WA
 May 2013 ASCO Annual Meeting
 June 2013 12th International Conference on Malignant Lymphoma, Lugano, Switzerland
 July 2013 FEBS Annual Meeting, St. Petersburg, Russia
 July 2013 FASEB Meeting on Molecular Mechanisms of Lymphocyte Development and Function, Steamboat Springs, CO
 Aug 2013 FASEB Meeting on Hematological Malignancies, Saxton’s River, VT
 Sept 2013 Program in Immunology Seminar Series, Harvard Medical School, Boston, MA
 Sept 2013 International Cancer Genome Project Annual Meeting, Toronto, Canada
 Oct 2013 Chabner Colloquium, Society for Translational Oncology, Boston, MA
 Nov 2013 Nature Medicine Conference on Cancer Therapeutics, La Jolla, CA
 Nov 2013 Beene Cancer Center Symposium, Memorial Sloan Kettering Cancer Center, New York, NY
 Dec 2013 American Society of Hematology Annual Meeting, New Orleans, LA
 Jan 2014 Univ. of California, San Francisco, Dept. of Immunology, San Francisco, CA
 Feb 2014 Keystone symposium on the Biology of B Cell Responses, Keystone, CO
 Feb 2014 Keystone symposium on the NF-kappaB System in Health and Disease, Keystone, CO
 Mar 2014 University of Pennsylvania Immunology Graduate Group, Philadelphia, PA
 Mar 2014 Jonathan Adam Jonas Lymphoma Memorial Lectureship, Washington Univ. Sch. of Medicine, St. Louis, MO
 Apr 2014 Opening Plenary Presentation, AACR Annual Meeting, San Diego, CA
 Apr 2014 Ipsen Foundation Symposium on Cancer Genomics, Chantilly, France
 Apr 2014 2014 Visiting Professor, Sass Foundation for Medical Research, New York, NY
 May 2014 Cancer Biology Seminar Series, Stanford Univ. School of Medicine, Palo Alto, CA
 June 2014 Ross Molecular Medicine Symposium, New York, NY
 June 2014 Les Treilles Foundation meeting: Overcoming Therapeutic Resistance to Defeat Cancer, Tourtour, France
 Aug 2014 ASH Meeting on Lymphoma Biology, Colorado Springs, CO
 Sept 2014 AACR meeting on PI(3) kinase, Philadelphia, PA
 Sept 2014 AACR meeting on hematological malignancies, Philadelphia, PA
 Oct 2014 Next Generation Cell Culture workshop, Cambridge, UK
 Oct 2014 Beth Israel New England Deaconess Medical Center Pathology Grand Rounds, Boston, MA
 Oct 2014 European Hematopathology Association Annual Meeting, Istanbul, Turkey
 Nov 2014 NCRI Cancer Research Meeting, Liverpool, UK
 Nov 2014 European Society of Hematology International Conference on Lymphoma, Thessaloniki, Greece

BIBLIOGRAPHY

Louis M. Staudt

1. Gerhard W, Yewdell J, Frankel ME, Lopes AD, **Staudt L**. Monoclonal antibodies against influenza virus. In: Kennett RH, McKearn TJ, Bechtol KB, eds. *Monoclonal Antibodies*. New York: Plenum 1980;137.
2. **Staudt L**, Frankel ME, Yewdell J, Gerhard W. Genetic variation in viruses analyzed with monoclonal antibodies. In: Bachman PA eds. *Biological Products for Viral Diseases*. London: Taylor and Francis 1980;147.
3. **Staudt, LM**. The idiotypic and paratypic relations of anti-influenza virus hemagglutinin antibodies produced by BALB/c mice. In: Berek C, Etlinger H, Gerhard W, eds. *Idiotypes: Antigens on the inside*. Basel: Roche 1981;49.
4. **Staudt LM**, Gerhard W, McKean DJ, Bell M, Luedtke R, Weigert M. Somatic mutation generates significant antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. In: *Proceedings of New Perspectives in Virology*. Rome: 1983;1102.
5. **Staudt LM**, Gerhard W. The generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I: Significant variation in repertoire expression between individual mice. *J Exp Med* 1983;157:687.
6. McKean D, Huppi K, Bell M, **Staudt L**, Gerhard W, Weigert M. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. *Proc Natl Acad Sci* 1984;81:3180.
7. Huppi K, Julius M, **Staudt L**, Gerhard W, Weigert M. The idiotypes of Vk21 light chains. *Paris: Les Annales d-Immunologie* 1984;135c:181.
8. Clarke SH, Huppi K, Ruezinsky D, **Staudt L**, Gerhard W, Weigert M. Inter- and Intraclonal diversity in the antibody response to influenza virus hemagglutinin. *J Exp Med* 1985;161:687.
9. Caton AJ, Brownlee GG, **Staudt LM**, Gerhard W. Germ-line and somatic diversity in the antibody response to the influenza virus hemagglutinin. In: *Current Communications in Molecular Biology*. NY: Cold Spring Harbor Laboratory 1985;35.
10. Clark SH, Huppi K, Ruezinsky D, **Staudt LM**, Gerhard W, Weigert M. Antibody diversity in the immune response to influenza virus hemagglutinin. In: *Current Communications in Molecular Biology*. NY: Cold Spring Harbor Laboratory 1985;39.
11. Caton AJ, Brownlee GG, **Staudt LM**, Gerhard W. Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin. *EMBO J* 1985;5:1577.
12. **Staudt LM**, Singh H, Sen R, Wirth T, Sharp PA, Baltimore D. A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. *Nature* 1986;323:640.
13. Wirth T, **Staudt LM**, Baltimore D. An octamer oligonucleotide upstream of a TATA motif is sufficient for lymphoid-specific promoter activity. *Nature* 1987;329:174.
14. **Staudt LM**, Clerc RG, Singh H, Lebowitz JH, Sharp PA, Baltimore D. Cloning of a lymphoid-specific cDNA encoding a protein binding the regulatory octamer DNA motif. *Science* 1988;241:577.
15. Ko HS, Fast P, McBride W, **Staudt LM**. A human protein specific for the immunoglobulin octamer DNA motif contains a functional homeobox domain. *Cell* 1988;55:135-44.
16. LeBowitz JH, Kobayashi T, **Staudt L**, Baltimore D, Sharp PA. Octamer-binding proteins from B or HeLa cells stimulate transcription of the immunoglobulin heavy-chain promoter in vitro. *Genes & Development* 1988;2:1227-37.

17. Lenardo MJ, **Staudt L**, Robbins P, Kuang A, Mulligan R, Baltimore D. Repression of the immunoglobulin heavy chain enhancer in mouse teratocarcinoma cells is associated with the presence of a novel octamer binding factor. *Science* 1989;243:544-6.
18. Takimoto M, Quinn JP, Farina AR, **Staudt LM**, Levens D. fos/jun and octamer-binding protein interact with a common site in a negative element of the human c-myc gene. *J Biol Chem* 1989;264:8992-9.
19. Petryniak B, **Staudt LM**, Postema C, McCormick WT, Thompson CB. Characterization of chicken octamer-binding proteins demonstrates that POU-containing homeotic transcription factors have been highly conserved during vertebrate evolution. *Proc Natl Acad Sci* 1990;87:1099-103.
20. Clark SH, **Staudt LM**, Kavalier J, Schwartz D, Gerhard WU, Weigert MG. V region gene usage and somatic mutation in the primary and secondary responses to influenza virus hemagglutinin. *J Immunol* 1990;144:2795-801.
21. Rosner MH, Vigano MA, Ozato K, Timmons PM, Poirier F, Rigby PWJ, **Staudt LM**. A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. *Nature* 1990;345:686-692.
22. Kavalier J, Caton AJ, **Staudt LM**, Schwartz D, Gerhard W. A set of closely related antibodies dominates the primary antibody response to the antigenic site CB of the A/PR/8/34 influenza virus hemagglutinin. *J Immunol* 1990;145:2312-21.
23. Clarke S, Rickert R, Wloch MK, **Staudt L**, Gerhard W, Weigert M. The BALB/c secondary response to the Sb site of influenza virus hemagglutinin. *J Immunol* 1990;145:2286-96.
24. **Staudt LM**, Lenardo MJ. Immunoglobulin gene transcription. *Annu Rev Immunol* 1991;9:373-98.
25. Siracusa LD, Rosner MH, Vigano MA, Gilbert DJ, **Staudt LM**, Copeland NG, Jenkins NA. Chromosomal location of the octamer transcription factors, Otf-1, Otf-2, and Otf-3, suggests close linkage to several mutant loci and defines multiple Otf-3-related sequences dispersed in the mouse genome. *Genomics* 1991;10:313-26.
26. Caton AJ, Stark SE, Kavalier J, **Staudt LM**, Schwartz D, Gerhard W. Many variable region genes are utilized in the antibody response of BALB/c mice to the influenza virus A/PR/8/34 hemagglutinin. *J Immunol* 1991;147:1675-86.
27. Kavalier J, Caton AJ, **Staudt LM**, Gerhard W. A B cell population that dominates the primary response to influenza virus hemagglutinin does not participate in the memory response. *Eur J Immunol* 1991;21:2687-95.
28. Kang S-M, Tsang W, Doll S, Scherle P, Ko H-S, Tran A-C, Lenardo MJ, **Staudt LM**. Induction of the POU domain transcription factor Oct-2 during T-cell activation by cognate antigen. *Mol Cell Biol* 1992;12:3149-3154.
29. Scherle P, Behrens T, **Staudt LM**. LyGDI, a GDP dissociation inhibitor of the rhoA GTP-binding protein, is expressed preferentially in lymphocytes. *Proc Natl Acad Sci USA* 1993;90:7568-72.
30. Behrens TW, Jagadeesh J, Scherle P, Kearns G, Yewdell J, **Staudt LM**. Jaw 1, a lymphoid-restricted membrane protein localized to the endoplasmic reticulum. *J Immunol* 1994;153:682-690.
31. **Staudt LM**, Dent A, Ma C, Allman D, Powell J, Maile R, Scherle P, Behrens T. Rapid identification of novel human lymphoid-restricted genes by automated DNA sequencing of subtracted cDNA libraries. *Curr Topics Microbiol Immunol* 1994;194:155-161.
32. Stewart DM, Notarangelo LD, Kurman CC, **Staudt LM**, Nelson DL. Molecular genetic analysis of X-linked agammaglobulinemia with isolated growth hormone deficiency. In: Caragol I, Espanol T, Fontan G, Matamoros N, eds. *Progress in immune deficiency V*. Proc of European group for immunodeficiencies. Barcelona: Springer-Verlag Ibérica 1995;52-54.
33. Stewart DM, Notarangelo LD, Kurman CC, **Staudt LM**, Nelson DL. Molecular genetic analysis of X-linked hypogammaglobulinemia and isolated growth hormone deficiency. *J Immunol* 1995;155:2770-2774.

34. Viganò MA, **Staudt LM**. Transcriptional activation by Oct-3. Evidence for a specific role of the POU-specific domain in mediating functional interaction with Oct-1. *Nucl Acids Res* 1996;24:2112-2118.
35. Sorbara LR, Maldarelli F, Chamoun G, Schilling B, Choekijcahi S, **Staudt L**, Mitsuya H, Simpson IA, Zeichner SL. Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression. *J Virol* 1996; 70:7275-7279.
36. Thornton AM, Ogryzko VV, Dent A, Sharf R, Levi B-Z, Kanno Y, **Staudt LM**, Howard BH, Ozato K. A dominant negative mutant of an IFN regulatory factor family protein inhibits both type I and type II IFN-stimulated gene. *J Immunol* 1996;157:5145-5154.
37. Behrens TW, Kearns G, Rivard JJ, Bernstein H, Yewdell J, **Staudt LM**. Carboxy-terminal targeting and novel post-translational processing of JAW1, a lymphoid protein of the endoplasmic reticulum. *J Biol Chem* 1996;271:23528-23534.
38. Dent A, Yewdell J, Puvion-Dutilleul F, Koken MHM, de Thé H, **Staudt LM**. LYSP100-associated nuclear domains ("LANDS"): A new class of sub-nuclear structures and their relationship to PML nuclear bodies. *Blood* 1996;88:1423-1436.
39. Ma C, **Staudt LM**. LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(1) leukemias. *Blood* 1996;87:734-745.
40. Liao X, Ma C, Trask B, Massa H, Gilbert DJ, **Staudt LM**, Jenkins NA, Copeland NG. LAF4 maps to mouse chromosome 1 and human chromosome 2q11.2-q12. *Mamm Genome* 1996; 7:467-468.
41. Allman D, Jain A, Dent A, Maile R, Selvaggi T, Kehry MR, **Staudt LM**. BCL-6 expression during B cell activation. *Blood* 1996;87:5257-5268.
42. Seyfert V, Allman D, He Y, **Staudt LM**. Transcriptional repression by the proto-oncogene BCL-6. *Oncogene* 1996;12:2331-2342.
43. Liao X, Gilbert DJ, Dent A, **Staudt LM**, Jenkins NA, Copeland, NG. Mapping of the mouse Bcl6 gene to chromosome 16. *Mamm Genome* 1996;7:621-622.
44. Dent AL, Shaffer A, Yu X, Allman D, **Staudt LM**. Control of inflammation, cytokine expression and germinal center formation by BCL-6. *Science* 1997;276:589-592.
45. Yin L, Arnheiter H, Scharton-Kersten TM, Schwartzberg P, Sher A, **Staudt LM**, Lenardo M. Immune responses in mice deficient in Ly-GDI, a lymphoid-specific regulator of rho GTPases. *Mol Immunol.* 1997; 34:481-491.
46. Dent AL, Hu-Li J, Paul WE, **Staudt LM**. TH2-type Inflammation in the Absence of IL-4 and STAT6. *Proc Natl Acad Sci*, 1998; 95:13823-13828.
47. Alizadeh A, Eisen M, Brown PO, **Staudt LM**. Probing Lymphocyte Biology by Genomic-scale Gene Expression Analysis. *J Clin Immunol*, 1998;18:373-379.
48. Iyer VR, Eisen MD, Ross DT, Schuler G, Moore T, Lee J, Trent JM, **Staudt LM**, Hudson J, Boguski M, Lashkari D, Shalon D, Botstein D, Brown PO. The transcriptional response of human fibroblasts to serum. *Science* 1999;283:83-87.
49. Dent AL, Shaffer A, Yu X, **Staudt LM**. Regulation of Lymphocyte Cell Fate Decisions and Lymphomagenesis by BCL-6. *Int Rev Immunol* 1999;18:381-403.
50. Carter KC, Annunziata CM, Barash S, **Staudt LM**, Dillon PJ, Fergusso, M, Rosen CA, Cossman J. Reed-Sternberg cell genome expression. *Blood*, 1999; 94:411-416.
51. Dent AL, Doherty, TM, Paul WE, Sher, A, **Staudt LM**. BCL-6-deficient mice reveal an IL-4-independent STAT6-dependent pathway that controls susceptibility to infection by *Leishmania major*. *J Immunol* 1999; 163:2098-2103.

- 52 Cossman J, **Staudt LM**, Raffeld M. Application of molecular genetics to the diagnosis of hematopoietic neoplasms. In *Neoplastic Hematopathology*, DM Knowles, Ed., 1999.
- 53 Alizadeh A, Eisen M, Davis RE, Ma CA, Sabet H, Tran T, Powell JI, Yang L, Marti GE, Moore DT, Hudson JR, Chan WC, Greiner T, Weisenberger D, Armitage JO, Lossos I, Levy R, Botstein D, Brown PO, **Staudt LM**. The Lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. *Cold Spring Harbor Symposium on Quantitative Biology*, 1999; 64:71-78.
- 54 **Staudt LM**. The molecular and cellular origins of Hodgkin's disease. *J Exp Med*, 2000; 191:207-212
- 55 Alizadeh A, Eisen M, Davis RE, Ma CA, Lossos I, Rosenwald A, Boldrick J, Sabet H, Tran T, Yu X, Powell J, Yang L, Marti G, Moore T, Hudson J, Chan WC, Greiner TC, Weissenberger DD, Armitage JO, Levy R, Grever MR, Byrd JC, Botstein D, Brown PO, **Staudt LM**. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 2000; 403:503-511.
- 56 Alizadeh AA, **Staudt LM**. Genomic-scale gene expression profiling of normal and malignant immune cells. *Curr Opin Immunol* 2000, 12:219-225.
- 57 **Staudt LM**. The expression of the genome during immune responses. *Curr Opin Immunol* 2000, 12:199-200.
- 58 **Staudt LM**, Brown PO. Genomic views of the immune system. *Annual Review of Immunology*, 2000, 18:829-859.
- 59 Hastie T, Tibshirani R, Eisen MB, Alizadeh A, Levy R, **Staudt L**, Chan WC, Botstein D, Brown P. 'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. *Genome Biology* 2000, 1:3.1-3.21.
- 60 Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D, **Staudt LM**, Levy R. Ongoing immunoglobulin heavy chain somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. *Proc Natl Acad Sci* 2000, 97:10209-10213.
- 61 Meffre E, Davis E, Schiff C, Cunningham-Rundles C, Ivashkiv LB, **Staudt LM**, Young JW, Nussenzweig MC. Circulating human B cells that express surrogate light chains and edited receptors. *Nature Immunology* 2000, 3:207-213.
- 62 Shaffer AL, Yu X, He Y, Boldrick J, Chan E, **Staudt LM**. BCL-6 represses genes that function in lymphocyte differentiation, inflammation and cell cycle control. *Immunity* 2000, 13:199-212.
- 63 Ma C, **Staudt LM**. Molecular definition of the germinal centre stage of B cell differentiation. *Phil. Trans. R. Soc. Lond. B* 2001, 356:83-89.
- 64 Feske S, Giltneane J, Dolmetsch R, **Staudt LM**, Rao A. Gene regulation mediated by calcium signals in T lymphocytes. *Nature Immunology* 2001, 2:316-324.
- 65 **Staudt LM**. Gene expression physiology and pathophysiology of the immune system. *Trends in Immunology* 2001, 22:35-40.
- 66 Boehm J, He Y, Greiner A, **Staudt L**, Wirth T. Regulation of BOB.1/OBF.1 stability by SIAH. *EMBO J.* 2001, 20:4153-4162.
- 67 Wandinger K-P, Sturzebecher C-S, Bielekova B, Detore G, Rosenwald A, **Staudt LM**, McFarland HF, Martin R. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. *Ann Neurol* 2001, 50:349-357.
- 68 Siebert R, Rosenwald A, **Staudt LM**, Morris S. Molecular features of B-cell lymphoma. *Current Opinion in Oncology* 2001, 13:316-324.
- 69 Shaffer AL, Rosenwald A, Hurt E, Giltneane J, Lam L, Pickett O, **Staudt LM**. Signatures of the immune response. *Immunity* 2001, 15:375-385.

- 70 **Staudt LM**, Flavell RA. Genomics, genetics and genes of the immune system. *Immunity* 2001, 15:335-336.
- 71 Lam L, Pickeral OK, Davis RE, Giltane J, Sathyamoorthy M, Yu X, Rosenwald A, Hurt E, Shaffer AL, Hollingshead M, Harris E, Monks A, Milovits J, Sausville E, **Staudt LM**. Genomic-scale measurement of mRNA turnover using the anti-cancer drug flavopiridol. *Genome Biology* 2001, 2:0041.1-0041.11.
- 72 Rosenwald A, Alizadeh AA, Widhopf, GF, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, **Staudt LM**. Relation of gene expression phenotype to immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia. *J Exp Med* 2001, 194:1639-1647.
- 73 Davis RE, Brown KD, Siebenlist U, **Staudt LM**. Constitutive nuclear factor κ B activity is required for survival of activated B-like diffuse large B-cell lymphoma cells. *J Exp Med* 2001, 194:1861-1874.
- 74 **Staudt LM**. Gene expression profiling of lymphoid malignancies. *Annual Review of Medicine* 2002, 53:303-318.
- 75 Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, Belcher CE, Botstein D, **Staudt LM**, Brown PO, Relman DA. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. *Proc Natl Acad Sci* 2002, 99:972-977.
- 76 Huang JZ, Pickering, DL, Sanger WG, **Staudt LM**, Greiner TC, Weisenburger DD, Armitage JO, Warnke RA, Levy R, Wu G, Lynch, JC, Chan WC. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma (DLBCL) with a germinal center B-cell gene expression profile. *Blood* 2002, 99:2285-2290.
- 77 Rosenwald A, **Staudt LM**. Clinical translation of gene expression profiling in lymphomas and leukemias. *Seminars in Oncology* 2002, 29:258-63.
- 78 Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, **Staudt LM**, Cheson, BD Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. *Blood* 2002, 99:2685-2693.
- 79 Davis RE, **Staudt LM**. Molecular diagnosis of lymphoid malignancies by gene expression profiling. *Current Opinion in Hematology* 2002, 9:333-8.
- 80 **Staudt LM**. It's ALL in the diagnosis. *Cancer Cell* 2002, 1:109-110.
- 81 Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, **Staudt LM**. The use of molecular profiling to predict survival after chemotherapy of diffuse large B-cell lymphoma. *N Engl J Med* 2004;1937-1947.
- 82 Shaffer AL, Lin K-I, Yu X, Hurt EM, Rosenwald A, Giltane JM, Zhao H, Calame K, **Staudt LM**. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. *Immunity*, 2002, 17:51-62.
- 83 Shaffer AL, Rosenwald A, **Staudt LM**. Lymphoid malignancies: the dark side of mature B cell differentiation and activation. *Nature Reviews Immunology* 2002, 2:1-13.
- 84 **Staudt LM**, Wilson WH. Focus on lymphoma. *Cancer Cell* 2002, 2:363-366.
- 85 Kalaitzidis D, Davis RE, Rosenwald A, **Staudt LM**, Gilmore TD. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF- κ B signal transduction pathway. *Oncogene* 2002, 21:8759-68.

- 86 Kovanen P, Rosenwald A, Fu J, Hurt EM, Lam LT, Giltane JM, Wright G, **Staudt LM**, Leonard W. Analysis of γ c-family cytokine target genes: Identification of DUSP5 as a regulator of MAP kinase activity in IL-2 signaling. *J Biol Chem* 2003, 278:5205-5213.
- 87 Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, **Staudt LM**. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. *Cancer Cell*, 2003, 3:185-197.
- 88 Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y, Bex F, Hermine O, **Staudt L**, de The H, Bazarbachi A. Arsenic/interferon specifically reverses two distinct gene networks critical for the survival of HTLV-I infected leukemic cells. *Blood* 2003, 101:4576-82.
- 89 Sanchez-Izquierdo D, Buchonnet G, Siebert R, Gascoyne RD, Climent J, Karran EL, Marin M, Blesa D, Horsman D, Rosenwald A, **Staudt LM**, Albertson DG, Du MQ, Ye H, Marynen P, Garcia-Conde J, Pinkel P, Dyer MJS, Martinez-Climent JA. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. *Blood* 2003, 101:4539-46.
- 90 Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, Frank JA, **Staudt L**, Martin R, McFarland HF. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. *Brain*. 2003, 126:1419-1429.
- 91 Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, **Staudt LM**. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. *Blood*, 2003, 101:4944-4951.
- 92 Pan Z, Shen Y, Du C, Zhou G, McKeithan T, Rosenwald A, **Staudt L**, Chan WC. Two newly characterized germinal center B-cell associated genes that have diagnostic and prognostic values in B-cell lymphoproliferative disorders. *Am J Pathol*, 2003, 163:135-44.
- 93 Wright GE, Tan B, Rosenwald A, Hurt EH, Wiestner A, **Staudt LM**. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. *Proc Natl Acad Sci* 2003, 100:9991-9996.
- 94 Staudt LM. Molecular diagnosis of the hematologic cancers. *N Engl J Med* 2003 348:1777-85.
- 95 Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao H, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, **Staudt LM**. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med* 2003, 198:1-12.
- 96 Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, **Staudt LM**, Oscier DG. ZAP-70 expression by flow cytometry is a good prognostic marker in CLL and a potential surrogate for immunoglobulin VH gene mutations. *Lancet* 2004, 363:105-111.
- 97 Wiestner A, **Staudt LM**. Towards molecular diagnosis and targeted therapy of lymphoid malignancies. *Sem Hematol* 2003, 40:296-307.
- 98 McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltane JM, Malani RB, **Staudt LM**, Licht JD. Growth suppression by acute promyelocytic leukemia-associated PLZF is mediated by repression of c-myc expression. *Mol Cell Biol* 2003, 23:9375-9388.

- 99 Rosenwald A, **Staudt LM**. Gene expression profiling of diffuse large B-cell lymphoma. *Leukemia and Lymphoma* 2003 Suppl. 3 44:S41-S47.
- 100 Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Lynch JC, Falini B, Banham AH, Rosenwald A, **Staudt LM**, Connors JM, Armitage JO, Chan WC. Molecular subclassification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood* 2004 103:275-82.
- 101 Weller S, Tan B, Rosenwald A, Braun MC, Cordier C, Conley M-E, Plebani A, Kumararatne DS, Bonnet D, Tournilhac O, Tchernia G, **Staudt LM**, Casanova J-L, Reynaud C-A, Weill J-C. Circulating IgM “memory” and splenic marginal zone B cells in humans define a unique B cell population. *Blood* 2004 104:3647-54.
- 102 Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Botstein D, Brown PO, Mitchell JB, Marti GE, Fowler DH, Wilson WH, **Staudt LM**. Fludarabine treatment of chronic lymphocytic leukemia patients induces a p53-dependent gene expression response. *Blood* 2004 104:1428-1434.
- 103 Cahir-McFarland ED, Carter K, Rosenwald A, Giltane J, Henrickson S, **Staudt LM**, Kieff E. Role of EBV latency III, LMP1 and NF- κ B in cell survival and gene expression. *J Virol* 2004 78:4108-4119.
- 104 Rimsza L, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel R, Weisenburger DD, Chan WC, Greiner TP, Muller-Hermelink K, Jaffe ES, Gascoyne RD, Campo E, Fuchs D, Spier CM, Fisher RI, **Staudt LM**, Grogan T. Loss of MHC class II gene and protein expression in diffuse large B cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival: A follow-up study to the NIH Director's Challenge Leukemia and Lymphoma Molecular Profiling Project. *Blood* 2004 103:4251-4258.
- 105 Rosenwald A, **Staudt LM**, Duyster JG, Morris SW. Molecular aspects of non-Hodgkin lymphomagenesis. In Wintrobe's Clinical Hematology 2004.
- 106 Nimmerjahn F, Dudziak D, Dirmeier U, Hobom G, Riedel A, Schlee M, **Staudt LM**, Rosenwald A, Behrends U, Bornkamm GW, Mautner J. Active NF- κ B signalling is a prerequisite for influenza virus infection. *J Gen Virol*. 2004 85:2347-2356.
- 107 Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave S, Cao K, Zhu Q, Xiao L, Sherman S, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Ott G, Müller-Hermelink HK, Delabie J, Braziel RM, Jaffe ES, Campo E, Lynch JC, Connors JM, Vose JM, Armitage JO, Grogan T, **Staudt LM**, Chan WC. BCL2 translocation defines a subset of DLBCL with germinal center B-cell-like gene expression profiles and preferential expression of a set of genes. *Am J Pathol* 2004 165:159-66.
- 108 Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, **Staudt LM**, Calame KL. Direct Repression of *prdm1* by Bcl-6 Inhibits Plasmacytic Differentiation. *J Immunol* 2004 173:1158-65.
- 109 Shen Y, Iqbal J, Xiao L, Lynch RC, Rosenwald A, **Staudt LM**, Sherman S, Dybkaer K, Zhou G, Eudy JD, Delabie J, McKeithan TW, Chan WC. Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs. *BMC Immunology*, 2004 5:20.
- 110 Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee A-H, Qian S-B, Zhao H, Yu X, Yang L, Tan BK, Rosenwald A, Hurt EM, Petroulakis E, Sonenberg N, Yewdell JW, Calame K, Glimcher LH, **Staudt LM**. XBP acts downstream of Blimp- to expand the secretory apparatus, promote organelle biogenesis, and increase protein synthesis during plasma cell differentiation. *Immunity* 2004, 21:81:93.
- 111 DeLeeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, Dyer MJ, **Staudt LM**, Martinez-Climent JA, Lam WL. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. *Hum Mol Genet*. 2004, 13:1827-37.

- 112 Hurt EM, Wiestner A, Rosenwald A, Campo E, Grogan T, Bergsagel PL, Kuehl WM, **Staudt LM**. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. *Cancer Cell* 2004 5:191-199.
- 113 **Staudt LM**. Negative feedback for B cells. *Nature* 2004 431:919-920.
- 114 Dave S, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel R, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp P, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, **Staudt LM**. Survival following diagnosis of follicular lymphoma is predicted by molecular features of non-malignant tumor-infiltrating immune cells. *New Engl J Med* 2004 351:2159-2169.
- 115 Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottel M, Nong Y, Wen D, Adams J, Dang L, **Staudt LM**. Small molecule inhibitors of IKK-Kinase are selectively toxic for subgroups of diffuse large B cell lymphoma defined by gene expression profiling. *Clinical Cancer Research* 2005 11:1-13.
- 116 Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Adam M, Mhaweck P, **Staudt LM**, Schwaller J. MALT and the API-MALT fusion act between CD and IKK and confer NF- κ B dependent proliferative advantage and resistance against FAS-induced cell death in B cells. *Blood* 2005 105:2891-2899.
- 117 **Staudt LM**. Molecular diagnosis of the lymphomas by gene expression profiling. In: *The Lymphomas*. GP Canellos, TA Lister, B Young, editors. 2005, in press.
- 118 **Staudt LM**, Dave, S. The biology of human lymphoid malignancies revealed by gene expression profiling. *Advances in Immunology* 2005, 87:163-208.
- 119 Petersen D, Chandramouli GVR, Geoghegan J, Hilburn J, Paarlberg J, Kim CH, Munroe D, Gangi L, Han J, Puri R, **Staudt L**, Weinstein J, Barrett JC, Green J, Kawasaki ES. Three microarray platforms: an analysis of their concordance in profiling gene expression. *BMC Genomics* 2005, 6:63.
- 120 Rubio-Moscardo F, Blesa D, Mestre C, Siebert R, Balasas T, Benito A, Rosenwald A, Climent J, Martinez JI, Schilhabel M, Karran EL, Gesk S, Esteller M, deLeeuw R, **Staudt LM**, Fernandez-Luna JL, Pinkel D, Dyer MJS, Martinez-Climent JA. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: *TRAIL-R1* and *TRAIL-R2* as candidate dosage-dependent tumor suppressor genes. *Blood* 2005 106:3214-22.
- 121 Mestre C, Rubio-Moscardo F, Rosenwald A, Climent J, Dyer MJ, **Staudt L**, Pinkel D, Siebert R, Martinez-Climent JA. Homozygous deletion of *SOCS1* in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. *Leukemia* 2005 19:1082-4.
- 122 Bea S, Zettl A, Wright G, Salaverria I, Jehn J, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, **Staudt LM**, Campo E, Rosenwald A. Diffuse large B cell lymphoma subtypes have distinct genetic profiles that influence tumor biology and improve gene expression-based survival prediction. *Blood* 2005 106:3183-90.
- 123 Fu K, Weisenburger DD, Greiner TC, Dave S, Chiorazzi M, Wright G, Gesk S, Siebert R, De Jong D, Jaffe ES, Delabie J, Ott G, Wilson W, Braziel RM, Dave BJ, Sanger WG, Smith LM, Müller-Hermelink HK, Campo E, Gascoyne RD, Rosenwald A, **Staudt LM**, Chan WC. Cyclin D1-negative mantle cell lymphoma: A gene expression profiling, genetic and clinicopathological study. *Blood* 2005 106:4315-21.
- 124 Park SS, Shaffer AL, Kim JS, duBois W, Potter M, **Staudt LM**, Janz S. Insertion of *Myc* into *Igh* accelerates peritoneal plasmacytomas in mice. *Cancer Research* 2005 65:7644-7652.
- 125 Han S-S, Shaffer AL, Peng L, Chung S-T, Lim J-H, Maeng S, Kim JS, McNeil N, Ried T, **Staudt LM**, Janz S. Molecular and cytological features of the mouse B-cell lymphoma line iMycEm-1. *Mol Cancer* 2005 4:40.

- 126 Greiner TC, Dasgupta C, Ho VV, Weisenburger DD, Smith LM, Lynch JC, Vose JM, Armitage JO, Braziel RM, Campo E, Delabie J, Gascoyne RD, Jaffe ES, Muller-Hermelink HK, Ott G, Rosenwald A, **Staudt LM**, Im MY, Karaman MW, Pike BL, Chan WC, Hacia JG. Mutation and genomic deletion status of *ATM* and *p53* confer specific gene expression profiles in mantle cell lymphoma. *Proc Natl Acad Sci* 2006 103:2352-7.
- 127 Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink K, Delabie J, Fisher RI, Unger JM, Leblanc M, **Staudt LM**, Jaffe ES, Gascoyne RD, Chan WC, Weisenberger DD, Greiner TC, Braziel RM, Miller TP. Loss of major histocompatibility class II expression in non-immune privileged site diffuse large B cell lymphoma is highly coordinated and not due to chromosomal deletions. *Blood* 2006 107:1101-7.
- 128 Iqbal J, Neppalli VT, Wright G, Dave B, Horsman DE, Rosenwald A, Fu K, Pickering DL, Lynch J, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Campo E, Ott G, Müller-Hermelink HK, Delabie J, Jaffe ES, Braziel RM, Grogan TM, Connors JM, Yulei S, Sanger WG, Vose JM, Armitage JO, **Staudt LM**, Chan WC. *BCL2* expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. *J Clin Oncol* 2006 24:961-8.
- 129 Spence SL, Shaffer AL, **Staudt LM**, Amde S, Manney S, Terry C, Weisz K, Nissley P. Transformation of Late Passage Insulin-Like Growth Factor-I Receptor Null Mouse Embryo Fibroblasts by SV40 T Antigen. *Cancer Res.* 2006 66:4233-9.
- 130 Roberts RA, Wright G, Rosenwald A, Jaramillo MA, Grogan TM, Miller TP, Frutiger Y, Chan WC, Gascoyne RD, Ott G, Muller-Hermelink HK, **Staudt LM**, Rimsza LM. Loss of MHC Class II gene and protein expression in primary mediastinal large B cell lymphoma is highly coordinated and related to poor patient survival. *Blood* 2006 108:311-8.
- 131 Liu H, Ippolito GC, Wall JK, Niu T, Probst L, Lee BS, Pulford K, Banham A, Stockwin L, Shaffer AL, **Staudt LM**, Das C, Dyer MJ, Tucker PW. Functional studies of *BCL11A*: Characterization of the conserved *BCL11A-XL* splice variant and its interaction with *BCL6* in nuclear paraspeckles of germinal center B cells. *Mol Cancer* 2006 5:18.
- 132 Sciammas R, Shaffer AL, Schatz JH, Zhao H, **Staudt LM**, Singh H. Graded expression of Interferon Regulatory Factor-4 coordinates isotype switching with plasma cell differentiation. *Immunity* 2006 25: 225-36.
- 133 Shaffer AL, Wright GW, Yang L, Ngo V, Lamy L, Lam L, Davis RE, **Staudt LM**. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. *Immunol Rev* 2006 210:67-85.
- 134 Dave SS, Fu K, Wright G, Lam LT, Kluijn P, Boerma E-J, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, **Staudt LM**. Molecular diagnosis of Burkitt's lymphoma. *New Engl J Med* 2006 354:2431-2442.
- 135 Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, Lam L, Dave S, Yang L, Powell J, **Staudt LM**. A loss-of-function RNA interference screen for molecular targets in cancer. *Nature* 2006 441:106-110.
- 136 Schlee M, Hölzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J, Eick D, Marinkovic D, Wirth T, Rosenwald A, **Staudt LM**, Eilers M, Baran-Marszak F, Fagard R, Feuillard J, Laux G, and Bornkamm GW. c-MYC activation impairs the NF- κ B and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. *Int J Cancer* 2007 120:1387-95.
- 137 Cuadros M, Dave S, Jaffe ES, Honrado E, Milne R, Alves J, Rodríguez J, Zajac M, Benitez J, **Staudt LM**, Martinez-Delgado B. Identification of a proliferation signature related to survival in nodal peripheral T cell lymphomas. *J Clin Oncol* 2007 25:3321-9.
- 138 Davis RE, Zhang Y-Q, Southall N, Inglese J, **Staudt LM**, Austin C, Auld DS. A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor. *Assay Drug Dev Technol* 2007 5:85-103.
- 139 Young KH, Weisenburger DD, Dave B, Smith L, Sanger W, Iqbal J, Campo C, Delabie J, Gascoyne RD, Ott G, Rimsza

- L, Müller-Hermelink HK, Jaffe ES, Rosenwald A, **Staudt LM**, Chan WC, Greiner TC. Mutations in the DNA-Binding Codons of *TP53*, Which are Associated with Decreased Expression of TRAIL Receptor-2, Predict for Poor Survival in Diffuse Large B-cell Lymphoma. *Blood* 2007 110:4396-405.
- 140 Davies AJ, Rosenwald A, Wright G, Lee A, Chiorazzi M, Zhao H, Last KW, Weisenburger DD, Chan WC, Delabie J, Braziel RM, Campo E, Gascoyne RD, Jaffe ES, Muller-Hermelink HK, Ott G, Calaminici M, Norton AJ, Goff LK, Fitzgibbon J, **Staudt LM**, and Lister TA. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. *Br J Hematol* 2007 136:286-93.
- 141 Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, **Staudt LM**, Smeland EB. Characterization of early human B cell development by gene expression profiling. *J Immunol* 2007 179:3662-71.
- 142 Kimm LR, deLeeuw RJ, Savage KJ, Rosenwald A, Campo E, Delabie J, Ott G, Muller-Hermelink HK, Jaffe ES, Rimsza LM, Weisenburger DD, Chan WC, **Staudt LM**, Connors JM, Gascoyne RD, Lam WL. Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. *Genes Chromosomes Cancer* 2007 46:1090-7.
- 143 Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, Fresquet V, Beltran E, Agirre X, Marugan I, Marin M, Rosenwald A, Sugimoto KJ, Wheat LM, Karran EL, Garcia JF, Sanchez L, Prosper F, **Staudt LM**, Pinkel D, Dyer MJS, Martinez-Climent JA. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. *Blood* 2007 109:271-80.
- 144 Dunleavy K, Davis RE, Landgren O, **Staudt LM**, Wilson WH. BCL-6 and Rituximab in Diffuse Large B-cell Lymphoma: Where are we? *Blood* 2007 109:843-4.
- 145 Iqbal J, Greiner TC, Patel K, Dave BJ, Smith L, Ji J, Wright G, Sanger WG, Pickering DL, Jain S, Horsman DE, Shen Y, Fu K, Weisenburger DD, Hans CP, Campo E, Gascoyne RD, Rosenwald A, Jaffe ES, Delabie J, Rimsza L, Ott G, Müller-Hermelink HK, Connors JM, Vose JM, McKeithan T, **Staudt LM**, Chan WC. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. *Leukemia* 2007 21:2332-43.
- 146 **Staudt LM**. A closer look at follicular lymphoma. *New Engl J Med* 2007 356:741-2.
- 147 Lenz G, **Staudt LM**. Pathobiology of Non-Hodgkin's Lymphoma. In Hoffman's Hematology, Fifth Edition, 2007.
- 148 Salaverria I, Zettl A, Bea S, Valls J, Moreno V, Hartmann E, Ott G, Wright G, Jehn P, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, de Jong D, Gascoyne RD, Connors JM, Grogan TM, Rimsza LM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink H-K, **Staudt LM**, Rosenwald A, Campo E. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. *J Clin Oncol* 2007 25:1216-22.
- 149 Kuo TC, Shaffer AL, Haddad J, Choi YS, Staudt LM, Calame K. Repression of BCL-6 is required for the formation of human memory B cells in vitro. *J Exp Med* 2007 204:819-30.
- 150 Wan F, Anderson DE, Barnitz RA, Snow A, Bidere N, Zheng L, Hegde V, Lam LT, **Staudt LM**, Levens D, Deutsch WA, Lenardo MJ. Ribosomal Protein S3: a KH domain protein found in NF- κ B complexes that mediates selective gene regulation. *Cell* 2007 131:927-39.
- 151 Wiestner A, Tehrani M, Chiorazzi M, Wright G, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, **Staudt LM**. Point mutations and genomic deletions in the Cyclin D1 gene create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma. *Blood* 2007 109:4599-4606 (plenary paper).

- 152 Lenz G, Nagel I, Siebert R, Roschke A, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, **Staudt LM**. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B-cell lymphoma. *J Exp Med* 2007 204:633-43.
- 153 Annunziata CM, Davis RE, Demchenko Y, Gabrea A, Lenz G, Wright G, Xiao W, Dave S, Zhao H, Hanamura I, Zhan F, Stephens O, Dang L, William Bellamy, Bargolie B, Shaughnessy JD, Jr, Kuehl WM, **Staudt LM**. Frequent engagement of the classical and alternative NF- κ B pathways by diverse genetic abnormalities promotes cell survival in multiple myeloma. *Cancer Cell* 2007 12:115-130.
- 154 Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, **Staudt L**, Jaffe ES, Janik J. Phase II study of dose-adjusted EPOCH and Rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. *J Clin Oncol* 2008 26:2717-24.
- 155 Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, **Staudt LM**, Wilson WH, Wiestner A, Rader C. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. *Clin Cancer Res* 2008 14:396-404.
- 156 Xie Y, Deng S, Thomas CJ, Liu Y, Zhang YQ, Rinderspacher A, Huang W, Gong G, Wyler M, Cayanis E, Aulner N, Többen U, Chung C, Pampou S, Southall N, Vidović D, Schürer S, Branden L, Davis RE, **Staudt LM**, Inglese J, Austin CP, Landry DW, Smith DH, Auld DS. Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NF κ B activity within two separate high-throughput screens of NF κ B activation. *Bioorg Med Chem Lett* 2008 18:329-35.
- 157 Salaverria I, Zettl A, Beà S, Dave S, Wright G, Hartmann EM, Boerma EG, Kluin PM, Ott G, Chan WC, Lopez-Guillermo A, Gascoyne RD, Delabie J, Rimsza L, Brazier R, Jaffe ES, **Staudt LM**, Müller-Hermelink HK, Campo E, Rosenwald A. Chromosomal alterations detected by comparative genomic hybridization (CGH) in subgroups of gene expression-defined Burkitt lymphoma. *Hematologica* 2008 93:1327-34.
- 158 Young KH, Leroy K, Møller MB, Colleoni GWB, Sánchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Brazier RM, Jaffe ES, Wilson WH, **Staudt LM**, Vose JM, Chan WC, Weisenburger DD, Greiner TC. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B cell lymphoma: An international collaborative study. *Blood* 2008 112:3088-98.
- 159 Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan WC, Rosenwald A, Gascoyne RD, **Staudt LM**. Cooperative signaling through the STAT3 and NF- κ B pathways in subtypes of diffuse large B cell lymphoma. *Blood* 2008 111:3701-13.
- 160 O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Chan WC, Gascoyne RD, Wright G, **Staudt LM**, Lister TA, Fitzgibbon J. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and a poorer overall survival. *Blood* 2008 112:3126-9.
- 161 Lam LT, Davis RE, Ngo VN, Lenz G, Wright G, Zhao H, Yu X, Dang L, **Staudt LM**. Compensatory IKK α activation of classical NF- κ B signaling during IKK β inhibition identified by an RNA interference sensitization screen. *Proc Natl Acad Sci* 2008, 105:20798-20803.
- 162 Lenz G, Wright G, Emre T, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam L, Shaffer AL, Xiao W, Powell J, Rosenwald A, Muller-Hermelink H-K, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, **Staudt LM**. Molecular subtypes of diffuse large B cell lymphoma arise by distinct genetic pathways. *Proc Natl Acad Sci* 2008 105:13520-5.
- 163 Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D,

- Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller T, Rimsza LM, Cook J, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink H-K, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, **Staudt LM**. Stromal gene signatures in large-B-cell lymphomas. *New Engl J Med* 2008 359:2313-23.
- 164 Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, **Staudt LM**. Oncogenic *CARD11* mutations in human diffuse large B cell lymphoma. *Science* 2008 319:1676-9.
- 165 Shaffer AL, Emre NCT, Lamy L, Ngo VN, Xiao W, Wright G, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, **Staudt LM**. IRF4 addiction in multiple myeloma. *Nature* 2008 454:226-231.
- 166 Meragelman T, Scudiero D, Davis RE, **Staudt LM**, McCloud T, Cardellina J, Shoemaker R. Inhibitors of the NF-kappaB activation pathway from *Cryptocarya rugulosa*. *J Nat Prod* 2009 72:336-339.
- 167 O'Shea DM, O'Riain C, Gupta M, Waters RA, Wrench D, Yang Y, Gribben J, Rosenwald A, Ott G, Rimsza LM, Holte H, Cazier JB, Johnson NA, Campo E, Chan WC, Gascoyne RD, Young BD, **Staudt LM**, Lister TA, Fitzgibbon J. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. *Blood* 2009 113:2298-301.
- 168 Rimsza LM, Chan WC, Gascoyne RD, Campo E, Jaffe ES, **Staudt LM**, Delabie J, Rosenwald A, Murphy SP. CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. *Hematologica* 2009 94:596-8.
- 169 Choi WWL, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Geng H, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, **Staudt LM**, Chan WC. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. *Clin Cancer Res* 2009 15:5494-502.
- 170 Faumont N, Durand-Panteix S, Schlee M, Grömminger S, Schuhmacher M, Hölzel M, Laux G, Mailhammer R, Rosenwald A, **Staudt LM**, Bornkamm GW, Feuillard J. c-Myc and Rel/NF-kB are the two master transcriptional systems activated in the latency III program of Epstein-Barr Virus-immortalized B-Cells. *J Virol* 2009 83:5014-27.
- 171 Coffey GP, Rajapaksa R, Liu R, Sharpe O, Kuo CC, Krauss SW, Sagi Y, Davis RE, **Staudt LM**, Sharman JP, Robinson WH, Levy S. Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. *J Cell Sci* 2009 122:3137-44.
- 172 Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, Gascoyne RD, Chan W-C, Braziel RM, Rimsza LM, Weisenburger DD, Delabie J, Jaffe ES, Lister A, Norton AJ, Fitzgibbon J, **Staudt LM**, Hartmann EM, Mueller-Hermelink H-K, Campo E, Ott G, Rosenwald A. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. *Blood* 2009 114:826-34.
- 173 Wilkinson ST, Fernandez DR, Murphy SP, Braziel RM, Campo E, Chan WC, Delabie J, Gascoyne RD, **Staudt LM**, Jaffe ES, Rosenwald A, Rimsza LM. Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. *Leuk Lymphoma*. 2009 50:1875-8.
- 174 Mozos A, Royo C, Hartmann E, De Jong D, Baró C, Valera A, Fu K, Weisenburger DD, Chan WC, Delabie J, Chuang SS, Jaffe ES, Dave S, Bahl M, Solé F, López-Guillermo A, Colomer D, **Staudt LM**, Rosenwald A, Ott G, Jares P, Campo E. SOX11 expression is highly specific of mantle cell lymphoma and identifies the cyclin D1 negative subtype. *Hematologica* 2009 94:1555-1562.
- 175 O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L, Fleischmann C, Mein CA, Crook T, Smith P, Kelly G, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Johnson N, Gascoyne RD, Reimer S, Braziel RM, Wright GW, **Staudt LM**, Lister TA, Fitzgibbon J. Array-based DNA methylation profiling in follicular lymphoma. *Leukemia* 2009 23:1858-66.

- 176 Wilkinson ST, Fernandez DR, Murphy SP, Braziel RM, Campo E, Chan WC, Delabie J, Gascoyne RD, **Staudt LM**, Jaffe ES, Rosenwald A, Rimsza LM. Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. *Leuk Lymphoma*. 2009 50:1875-8.
- 177 Shaffer AL, Emre T, Rommesser P, **Staudt LM**. IRF4: Immunity. Malignancy! Therapy? *Clin Cancer Res* 2009 15:2954-61.
- 178 Vi JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, **Staudt LM**, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ, Khan J. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. *J Clin Invest*. 2009 119:3395-407.
- 179 Hailfinger S, Lenz G, Ngo V, Posevitz-Fejfar A, Rebeaud F, Guzzardi M, Murga Penas EM, Dierlamm J, Chan WC, **Staudt LM**, Thome M. Essential role of MALT1 protease activity in activated B cell-like diffuse large B cell lymphoma. *Proc Natl Acad Sci* 2009 106:19946-51.
- 180 Bidère N, Ngo VN, Lee J, Collins C, Zheng L, Wan F, Davis RE, Lenz G, Anderson DE, **Staudt LM***, Lenardo MJ*. Role for casein kinase 1 α in antigen receptor-induced NF- κ B and human lymphoma cell survival. *Nature* 2009 458:92-6. *co-senior authors
- 181 Dunleavy K, Pittaluga S, Czuczman M, Dave S, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, **Staudt LM***, Wilson WH*. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B cell lymphoma. *Blood* 2009 113:6069-76. *co-senior authors
- 182 Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, **Staudt LM**, Soucy TA, Yu J, Zhang J, Bolen JB, Smith PG. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- κ B-dependent lymphoma. *Blood* 2010 116:1515-23.
- 183 Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P, Xiao W, Braziel RM, Rimsza LM, Chan WC, Weisenburger DD, Delabie J, Jaffe ES, Gascoyne RD, Dave SS, Mueller-Hermelink HK, **Staudt LM**, Ott G, Bea SM, Rosenwald A. Pathway discovery in mantle cell lymphoma by integrated analysis of high resolution gene expression and copy number profiling. *Blood* 2010 116:953-61.
- 184 Wang Y, Ngo VN, Marani M, **Staudt LM**, Downward J. Critical role for the transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. *Oncogene* 2010 29:4658-70.
- 185 Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, **Staudt LM**, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classical Hodgkin lymphoma. *New Engl J Med* 2010 362:875-85.
- 186 **Staudt LM**. Oncogenic activation of NF- κ B. In Karin M, **Staudt LM** eds. NF- κ B, a Network Hub Controlling Immunity, Inflammation, and Cancer. Cold Spring Harbor Press 2010 2(6):a000109.
- 187 Lenz G, **Staudt LM**. Aggressive lymphomas. *New Engl J Med* 2010 362:1417-1429.
- 188 Davis RE, Ngo, VN, Lenz G, Tolar P, Young R, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell P, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, **Staudt LM**. Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma. *Nature* 2010 463:88-92.

- 189 Rui L, Emre NCT, Kruhlak MJ, Chung HJ, Lenz G, Wright GW, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Levens D, **Staudt LM**. Cooperative epigenetic modulation by cancer amplicon genes. *Cancer Cell* 2010 18:590-605.
- 190 Cardesa-Salzmänn TM, Colomo L, Gutierrez G, Chan WC, Weisenburger D, Climent F, González-Barca E, Mercadal S, Arenillas L, Serrano S, Tubbs R, Delabie J, Gascoyne RD, Connors JM, Mate JL, Rimsza L, Brazier R, Rosenwald A, Lenz G, Wright G, Jaffe ES, **Staudt LM**, Jares P, López-Guillermo A, Campo E. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. *Hematologica* 2011 96:996-1001.
- 191 Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, Chan WC, Brazier RM, Rimsza LM, Weisenburger DD, Delabie J, Jaffe ES, Fitzgibbon J, **Staudt LM**, Mueller-Hermelink HK, Calaminici M, Campo E, Ott G, Hernández L, Rosenwald A. MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. *Blood* 2011, 118:5550-8.
- 192 Eberle FC, Rodriguez-Canales J, Wei L, Hanson JC, Killian JK, Sun HW, Adams LG, Hewitt SM, Wilson WH, Pittaluga S, Meltzer PS, **Staudt LM**, Emmert-Buck MR, Jaffe ES. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and mediastinal large B-cell lymphoma. *Hematologica* 2011, 96:558-66.
- 193 Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti E, Chapman C, Mo C, Stennett L, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Arthur D, Maric I, Wilson WH, **Staudt LM**, Wiestner A. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. *Blood* 2010 117:542-52.
- 194 Rimsza LM, Wright GW, Schwartz M, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Cook J, Tubbs R, Brazier RM, Delabie J, Miller TP, **Staudt LM**. Accurate classification of diffuse large B cell lymphoma into germinal center and activated B cell subtypes using a nuclease protection assay on formalin fixed paraffin embedded tissues. *Clin Cancer Res* 2011 17:3727-3732.
- 195 Iqbal J, Meyer PN, Smith L, Johnson NA, Vose JM, Greiner TC, Connors J, **Staudt LM**, Rimsza LM, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Brazier RM, Cook J, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan W. BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-Cell Lymphoma Treated with CHOP-like therapy and Rituximab. *Clin Cancer Res*. 2011, 17:7785-7795.
- 196 Martinez-Garcia E, Popovic R, Sweet SMM, Heffner A, Thomas PM, Zamdborg L, Min DJ, Will C, Lamy L, **Staudt LM**, Levens DL, Kelleher NL, Licht JD. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. *Blood* 2011 117:211-20.
- 197 Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, Ott G, Rosenwald A, Brazier R, Campo E, Vose J, Lenz G, **Staudt L**, Chan W, Weisenburger DD. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. *Am J Clin Pathol* 2011 135:54-61.
- 198 Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, Ott G, Rosenwald A, Brazier RM, Campo E, Vose JM, Lenz G, **Staudt LM**, Chan WC, Weisenburger DD. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. *J Clin Oncol* 2011 29:200-7.
- 199 Steidl C, Shah SP, Woolcock BW, Rui L, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza L, Horsman DE, **Staudt LM**, Marra MA, Gascoyne RD. Recurrent rearrangement of MHC class II transactivator *CIITA* in B cell lymphomas. 2011 *Nature* 471:377-81.
- 200 Annunziata CM, Davis RE, Hernandez LF, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, **Staudt LM**. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. *Blood* 2011 117:2396-404.

- 201 Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, **Staudt LM**. Oncogenically active MYD88 mutations in human lymphoma. *Nature* 2011 470:115-119.
- 202 Rui L, Schmitz R, Ceribelli M, **Staudt LM**. Malignant pirates of the immune system. *Nature Immunology* 2011 12:933-40.
- 203 Johnson N, Slack G, Savage K, Connors J, Ben-Neriah S, Rogic A, Scott D, Tan Y, Steidl C, Horsman D, Sehn L, Chan W, Iqbal J, Meyer P, Lenz G, Wright G, Rimsza L, Valentino C, Brunhoeber P, Grogan T, Braziel R, Cook J, Tubbs R, Weisenburger D, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe E, **Staudt L**, Gascoyne R. Concurrent expression of MYC and BCL2 in R-CHOP treated diffuse large B cell lymphoma. *J Clin Oncol* 2012 30:3452-9.
- 204 Rao E, McKeithan T, Jiang C, Ji M, Iqbal J, Wright G, **Staudt LM**, Zhao Y, Chan WC, Fu K. The miR-17~92 cluster enhances resistance to chemotherapy in mantle cell lymphoma by down-regulating PTEN, PHLPP2 and BIM collaboratively. *Leukemia* 2012 26:1064-72.
- 205 Kentsis A, Reed C, Rice K, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk P, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Heinrichs S, Moreau L, Byers RJ, Christensen JG, Vande Woude G, Licht J, Kung A, **Staudt LM**, Look AT. Aberrant expression of hepatocyte growth factor induces autocrine activation of MET, providing a novel therapeutic target in acute myeloid leukemia. *Nature Medicine* 2012 18:1118-22.
- 206 Iqbal J, Shen Y, Liu Y, Fu K, Jaffe ES, Liu C, Liu Z, Deffenbacher K, Lachel CM, Greiner TC, Vose JM, Bhagavathi S, **Staudt LM**, Rimsza LM, Rosenwald A, Ott GK, Delabie J, Campo E, Braziel R, Tubbs RR, Cook JR, Gascoyne RD, Armitage JO, Weisenburger D, McKeithan TW, Chan WC. Genome-wide microRNA profiling of mantle cell lymphoma reveal a distinct subgroup with poor prognosis. *Blood* 2012 119:4939-48.
- 207 Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson C, **Staudt LM**, Young RA, Look AT. Core transcriptional regulatory circuit controlled by the TAL complex in human T-cell acute lymphoblastic leukemia. *Cancer Cell* 2012 22:209-21.
- 208 Deffenbacher KE, Iqbal J, Sanger W, Shen Y, Lachel C, Liu Z, Liu Y, Lim MS, Perkins SL, Fu K, Smith L, Lynch J, **Staudt LM**, Rimsza LM, Jaffe E, Rosenwald A, Ott GK, Delabie J, Campo E, Gascoyne RD, Cairo MS, Weisenburger DD, Greiner TC, Gross TG, Chan WC. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. *Blood* 2012 119:3757-66.
- 209 Perry AM, Cardesa-Salzman TM, Meyer PN, Colomo L, Smith LM, Fu K, Greiner TC, Delabie J, Gascoyne RD, Rimsza L, Jaffe ES, Ott G, Rosenwald A, Braziel RM, Tubbs R, Cook JR, **Staudt LM**, Connors JM, Sehn LH, Vose JM, López-Guillermo A, Campo E, Chan WC, Weisenburger DD. A new biological prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. *Blood* 2012 120:2290-6.
- 210 Snow AL, Xiao W, Stinson JR, Lu W, Chaigne-Delalande B, Zheng L, Pittaluga S, Matthews HF, Schmitz R, Jhavar S, Kuchen S, Kardava L, Wang W, Lamborn IT, Jing H, Raffeld M, Moir S, Fleisher TA, **Staudt LM**, Su HC, Lenardo MJ. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. *J Exp Med* 2012 209:2247-61.
- 211 Wan X, Yeung C, Kim SY, Dolan JG, Ngo VN, Burkett S, Khan J, **Staudt LM**, and Helman LJ. Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma. *Cancer Res* 2012 72:5889-99.
- 212 Chen E, **Staudt LM**, Green AR. Janus kinase deregulation in leukemia and lymphoma. *Immunity* 2012 36:529-41.
- 213 Landgren O, **Staudt LM**. MYD88 L265P somatic mutation in IgM MGUS. *New Engl J Med* 2012 367:2255-6.
- 214 Shaffer AL, **Staudt LM**. The case of the missing MYC. *Nature Immunology* 2012 13:1029-31.

- 215 Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, Shaffer AL 3rd, Louie T, Chen I, Randolph S, Hahn WC, **Staudt LM**, Niesvizky R, Moore MA, Chen-Kiang S. Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. *Blood* 2012 120:1095-106.
- 216 Lim K, Yang Y, **Staudt LM**. Pathogenetic importance and therapeutic implications of NF- κ B in lymphoid malignancies. *Immunol Rev* 2012 246:359-78.
- 217 Shaffer AL, Young RM, **Staudt LM**. Pathogenesis of human B cell lymphomas. *Ann Rev Immunol* 2012 30:565-610.
- 218 Yang Y, Shaffer AL, Emre NCT, Ceribelli M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Balasubramanian S, Buggy JJ, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, **Staudt LM**. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. *Cancer Cell* 2012 21:723-737.
- 219 Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson D, Buras E, Lu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, **Staudt LM**. Pathogenetic mechanisms and therapeutic targets in Burkitt lymphoma from structural and functional genomics. *Nature* 2012 490:116-20.
- 220 Young RM, **Staudt LM**. A new “brew” of MALT1 inhibitors. *Cancer Cell* 2012 22:706-7.
- 221 Huang X, Meng B, Iqbal J, Ding BB, Perry AM, Cao W, Smith LM, Bi C, Jiang C, Greiner TC, Weisenburger D, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel R, Gascoyne R, Cook J, Tubbs R, Jaffe E, Armitage J, Vose J, **Staudt L**, McKeithan TW, Chan W, Ye BH, Fu K. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma patients treated with R-CHOP. *J Clin Oncol* 2013 31:4520-8.
- 222 Bödör C, Grossmann V, Popov N, Okosun J, O’Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, **Staudt LM**, Wright G, Lister AT, Elemento O, Hills RK, Gribben J, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J. *EZH2* mutations are frequent and represent an early event in follicular lymphoma. *Blood* 2013 122:3165-8.
- 223 Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, **Staudt LM**, Helman LJ. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. *Oncogene* 2013 32:5429-38.
- 224 Dunleavy K, Pittaluga S, Shovlin M, Steinberg S, Cole D, Grant C, Widemann B, **Staudt LM**, Jaffe E, Little R, Wilson W. Low-intensity therapy in Burkitt lymphoma. *New Engl J Med* 2013 369:1915-25.
- 225 O’Shea JJ, Holland SM, **Staudt LM**. Mechanisms of Disease: JAKs and STATs in immunity, immunodeficiency, and cancer. *New Engl J Med* 2013 368:161-170.
- 226 Sawai CM, Sisirak V, Ghosh HS, Hou EZ, Ceribelli M, **Staudt LM**, Reizis B. Transcription factor Runx2 controls the development and migration of plasmacytoid dendritic cells. *J Exp Med* 2013 210:2151-9.
- 227 Enjuanes A, Albero R, Clot G, Navarro A, Beà S, Pinyol M, Martín-Subero JI, Klapper W, **Staudt LM**, Jaffe ES, Rimsza L, Braziel RM, Delabie J, Cook JR, Tubbs RR, Gascoyne R, Connors JM, Weisenburger DD, Greiner TC, Chan WC, López-Guillermo A, Rosenwald A, Ott G, Campo E, Jares P. Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. *Int J Cancer*. 2013 133:2852-63.
- 228 Lim KH, **Staudt LM**. Toll-like receptor signaling. *Cold Spring Harb Perspect Biol*. 2013 Jan 1;5(1). pii: a011247. doi: 10.1101/cshperspect.a011247.

- 229 Xiao W, Tran B, **Staudt LM**, Schmitz R. High-throughput RNA sequencing in B-cell lymphomas. *Methods Mol Biol* 2013 971:295-312.
- 230 Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Weng A, Ma W, Tatarek J, Fleischman, AG, Ahn Y, Yang Y, Zhou W, Kleppe M, Levine R, Neuberger DS, Moriggl R, Muller, M, Kelliher MA, Jamieson, CHM, Gray NS, **Staudt LM**, Druker BJ, Look AT. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. *Cancer Discovery* 2013 3:564-77.
- 231 Barlow J, Faryabi RB, Callen E, Wong N, Malhowski A, Chen HT, Gutierrez-Cruz G, McKinnon P, Robbiani D, **Staudt LM**, Fernandez-Capetillo O, Nussenzweig A. Identification of early replicating fragile sites that contribute to genomic instability in B cell lymphomas. *Cell* 2013 152:620-32.
- 232 Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, **Staudt LM**, Jaffe ES, Wilson WH. Dose-adjusted-EPOCH-R therapy in primary mediastinal B-cell lymphomas. *New Engl J Med* 2013 368:1408-16.
- 233 **Staudt LM**. Therapy of DLBCL based on genomics. *Hematol Oncol.* 2013 Suppl 1:26-8.
- 234 Mathews LA, Keller JM, McKnight C, Michael S, Shinn P, Liu D, **Staudt LM**, Thomas CJ, Ferrer M. Multiplexing high-content flow (HCF) and quantitative high-throughput screening (qHTS) to identify compounds capable of decreasing cell Viability, activating caspase 3/7, expressing annexin V, and changing Mitochondrial membrane integrity. *Curr Protoc Chem Biol.* 2013 5:195-212.
- 235 Young RM, **Staudt LM**. Targeting pathological B cell receptor signaling in lymphoid malignancies. *Nature Reviews Drug Discovery* 2013 12:229-43.
- 236 Chiorazzi M, Rui L, Yang Y, Ceribelli M, Tishbi N, Maurer CW, Zhao H, Xu W, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza L, Shaham S, **Staudt LM**. An evolutionarily conserved ubiquitin ligase for CED-9/BCL2. *Proc Natl Acad Sci* 2013 110:3943-8.
- 237 Lamy L, Ngo VN, Emre NCT, Shaffer AL, Yang Y, Tian E, Shaughnessy J, Nair V, Zingone A, Landgren O, **Staudt LM**. Control of autophagic cell death by caspase-10 in multiple myeloma. *Cancer Cell* 2013 23:435-49.
- 238 Mathews LA, Keller JM, McKnight C, Michael S, Shinn P, Liu D, **Staudt LM**, Thomas CJ, Ferrer M. Multiplexing high-content flow (HCF) and quantitative high-throughput screening (qHTS) to identify compounds capable of decreasing cell viability, activating caspase 3/7, expressing annexin V, and changing mitochondrial membrane integrity. *Curr Protoc Chem Biol.* 2013 5:195-212.
- 239 Kendrick S, Redd L, Muranyi A, Henricksen LA, Stanislaw S, Smith LM, Perry AM, Fu K, Weisenburger DD, Rosenwald A, Ott G, Gascoyne RD, Jaffe ES, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, **Staudt LM**, Chan WC, Steidl C, Grogan TM, Rimsza L. BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B cell lymphoma. *Human Pathology* 2014 45:2144-53.
- 240 Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W, Kucuk C, Rinaldi A, Bertoni F, Fitzgibbon J, Fu K, Weisenburger DD, Greiner TC, Dave BJ, Gascoyne RD, Rosenwald A, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors J, **Staudt LM**, and Chan WC. Genome-wide copy number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. *Blood* 2014 123:1681-90.
- 241 Roschewski M, **Staudt LM**, and Wilson W. Diffuse large B cell lymphoma-treatment approaches in the molecular era. *Nat Rev Clin Oncol* 2014 11:12-23.
- 242 Ippolito GC, Dekker JD, Wang YH, Lee BK, Shaffer AL 3rd, Lin J, Wall JK, Lee BS, **Staudt LM**, Liu YJ, Iyer VR, Tucker HO. Dendritic cell fate is determined by BCL11A. *Proc Natl Acad Sci* 2014 111:E998-E1006.

- 243 Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott GK, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, **Staudt LM***, Gascoyne RD*, Rimsza LM*. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue. *Blood* 2014 123:1214-7. *co-senior authors
- 244 Mathews L, Guha R, Shinn P, Lim KH, Young RM, Keller J, Liu D, Yasgar A, McKnight C, Boxer MB, Duveau DY, Jiang JK, Michael S, Mierzwa T, Walsh MJ, Mott BT, Patel PR, Leister W, Maloney DJ, Leclair CA, Rai G, Jadhav A, Peyser BD, Austin CP, Martin S, Simeonov A, Ferrer M, **Staudt LM***, Thomas CJ*. High-throughput combination screening identifies drug-drug pairings for the Bruton's tyrosine kinase inhibitor ibrutinib against diffuse large B-cell lymphoma. *Proc Natl Acad Sci* 2014 111:2349-54. *co-senior authors
- 245 Schmitz R, Ceribelli M, Pitaluga S, Wright G, and **Staudt LM**. Oncogenic mechanisms in Burkitt lymphoma. *Cold Spring Harb Perspect Med*. 2014 4:1-13.
- 246 Ghosh HS, Ceribelli M, Matos I, Lazarovici A, Bussemaker H, Lasorella A, Hiebert SW, Liu K, **Staudt LM**, Reizis B. ETO family protein Mtg16 regulates the balance of dendritic cell subsets by repressing Id2. *J Exp Med* 2014 211:1623-35.
- 247 Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, Williams M, **Staudt L**, Doroshow J. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. *Am Soc Clin Oncol Educ Book* 2014:71-6.
- 248 Young RM, **Staudt LM**. Ibrutinib treatment of CLL – the cancer fights back. *Cancer Cell* 2014 26:11-13.
- 249 Iqbal J*, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC*, **Staudt LM***. Gene expression signatures delineate biologic and prognostic subgroups in peripheral T-cell lymphoma. *Blood* 2014 123:2915-23 (plenary paper) *co-senior authors
- 250 Yang Y, Schmitz R, Mitala J, Whiting A, Xiao W, Ceribelli M, Wright G, Zhao H, Yang Y, Xu W, Rosenwald A, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Wiestner A, Kruhlak MJ, Iwai K, Bernal F, **Staudt LM**. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. *Cancer Discovery* 2014 4:480-93.
- 251 Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM, Roschewski M, **Staudt LM**, Jaffe ES, Dunleavy K. A prospective study of mediastinal gray zone lymphoma. *Blood* 2014 124:1563-9.
- 252 Muppidi JR, Schmitz R, Green JA, Xiao W, Larsen AB, Braun SE, An J, Xu Y, Rosenwald A, Ott G, Gascoyne RD, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Vaidehi N, **Staudt LM***, Cyster JG*. Loss of signaling via Gα13 in germinal center B cell-derived lymphoma. *Nature* 2014 516: 254-8. *co-senior authors
- 253 Ceribelli M, Kelly P, Shaffer AL, Wright G, Yang Y, Mathews-Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, Sandy P, Normant E, Thomas CJ, **Staudt LM**. Blockade of oncogenic IκB kinase activity in ABC DLBCL by small molecule BET protein inhibitors. *Proc Natl Acad Sci* 2014 111:11365-70.
- 254 Qian J, Wang Q, Dose M, Pruett N, Kieffer-Kwon KR, Resch W, Liang G, Tang Z, Mathé E, Benner C, Dubois W, Nelson S, Vian L, Oliveira TY, Jankovic M, Hakim O, Gazumyan A, Pavri R, Awasthi P, Song B, Liu G, Chen L, Zhu S, Feigenbaum L, **Staudt L**, Murre C, Ruan Y, Robbiani DF, Pan-Hammarström Q, Nussenzweig MC, Casellas R. B Cell Super-Enhancers and Regulatory Clusters Recruit AID Tumorigenic Activity. *Cell* 2014, in press.

- 255 Nakagawa M, Schmitz R, Xiao W, Goldman CK, Xu W, Yang Y, Yu X, Waldmann TA, **Staudt LM**. Gain-of-function *CCR4* mutations in adult T-cell leukemia/lymphoma. *J Exp Med* 2014, in press.
- 256 Yang Y, **Staudt LM**. Protein ubiquitination in lymphoid malignancies. *Immunological Reviews* 2014, in press.
- 257 Kelly PN, Chaudhary D, Yang Y, Shaffer AL, Romero DL, Robinson S, Young R, Geddes B, Westlin WF, Kapeller R, **Staudt LM**. Highly potent and selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of lymphoid malignancies. 2014, submitted.
- 258 Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, **Staudt LM**. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. 2014, submitted.